JPRN-UMIN000048347Recruiting未知
Retrospective study regarding tumor mutational burden (TMB) based on the Center for Cancer Genomics and Advanced Therapeutic (C-CAT) database - Retrospective study regarding tumor mutational burden (TMB) based on the Center for Cancer Genomics and Advanced Therapeutic (C-CAT) database
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University0 sites11,984 target enrollmentStarted: July 12, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 11,984
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients having provided no consent to get own data registered to C-CAT and for secondary use.
Investigators
Similar Trials
Completed
Not Applicable
A retrospective study of malignant transformation of ovarian teratoma(KCOG-G1305s)Ovarian cancerJPRN-UMIN000011153Kansai clinical oncology group200
Recruiting
Not Applicable
Investigation of tumor evolution in sporadic and tumor disposition syndrome-associated tumorstumors in patients with a tumor predisposition syndromesporadic tumorsC00-C97D00-D09D10-D36D37-D48Malignant neoplasmsIn situ neoplasmsBenign neoplasmsNeoplasms of uncertain or unknown behaviourDRKS00030089niversitätsklinikum Augsburg, Medizinische Fakultät, Universität Augsburg2,000
Recruiting
Not Applicable
Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of WürzburgC00-C97Malignant neoplasmsDRKS00029051niversitätsklinikum Würzburg998
Recruiting
Not Applicable
Observational study on gene mutation and prognosis for patients with resectable pancreatic cancerpancreatic cancerJPRN-UMIN000032917Kobe university219
Active, not recruiting
Not Applicable
A study to assess the incidence in the UK of a change in a protein found in patients with newly diagnosed non-small cell lung cancer which has advanced or spread, and to investigate the quality of life of these patients when they receive treatment with erlotinib (Tarceva®) alone as a first treatment for this stage of their disease.EUCTR2010-021120-96-GBRoche Products Limited1,200